An unfamiliar designer benzodiazepine has appeared behind a familiar alprazolam imprint.
In April 2026, the Center for Forensic Science Research and Education’s NPS Discovery program reported finding ethylflualprazolam in a rectangular blue tablet marked “B707” that originated in Georgia. Laboratory testing also identified 4′-Cl deschloroalprazolam, another novel benzodiazepine, in the same tablet.
The sample was received on April 6 and reported on April 28. Scientists confirmed the ethylflualprazolam finding with advanced mass-spectrometry techniques and authenticated reference material.
The B707 imprint matters because a legitimate B707 tablet is supposed to contain 2 mg of alprazolam, the generic medication commonly associated with the brand name Xanax. Someone who recognizes the blue rectangular pill may therefore assume they know its strength and effects. An unregulated tablet carrying the same imprint may create that expectation without providing any of the safeguards of a pharmacy-dispensed medication.
This finding should be treated as a regional early-warning signal, not proof that every blue B707 pill is counterfeit. CFSRE reported one Georgia drug-material sample and had not detected ethylflualprazolam in its toxicology specimens at the time of publication. The report also does not prove that this specific pill or batch has crossed into Tennessee.
It is still especially relevant to our region. Tennessee and Georgia share a border, and Brooks Healing Center serves people from the Chattanooga corridor as well as Georgia, including Marietta, Cobb County, and the greater Atlanta area. An early alert gives families, coalitions, clinicians, first responders, and treatment providers time to educate the community before a single detection becomes a wider pattern. Brooks is located a few hours from Marietta and offers detoxification and residential treatment to people traveling from Georgia.
The essential message: A pharmaceutical imprint identifies what a regulated product is intended to contain. It does not authenticate a loose pill obtained outside a licensed pharmacy.
Think someone took a fake “B707” or an unknown pill?
The Georgia B707 Finding at a Glance
Think someone took a fake “B707” or an unknown pill?
In an emergency — if a person can’t be woken, is breathing slowly or not at all, is making gurgling or snoring sounds, has had a seizure, or has blue, gray, or clammy skin — call 911 now. Give naloxone (Narcan) if you have it: it will not reverse a benzodiazepine, but it can reverse fentanyl or another opioid that may also be in the pill. Stay with the person until help arrives.
Worried about someone’s use, or your own? An unregulated pill can’t be identified by its color or imprint, and stopping daily benzodiazepine use suddenly can cause seizures. Brooks Healing Center provides medically supervised benzodiazepine detox and treatment for people across Tennessee and North Georgia. Call 931-486-8824 to talk with our admissions team or verify your insurance — confidentially, with no obligation.
| Category | Laboratory Finding |
|---|---|
| Reported substance | Ethylflualprazolam |
| Drug class | Novel or designer benzodiazepine |
| Other drug identified | 4′-Cl deschloroalprazolam |
| Tablet appearance | Rectangular blue tablet marked “B707” |
| Reported origin | Georgia |
| Sample type | Drug material |
| Date received | April 6, 2026 |
| Report date | April 28, 2026 |
| Testing used | GC-MS and LC-QTOF-MS with comparison to authenticated reference material |
| Dose reported? | No quantitative dose was provided in the public monograph |
| Alprazolam-equivalent strength available? | No |
| Clinical outcome reported? | No; this was a drug-material sample rather than a patient toxicology case |
| Number of CFSRE drug-material detections at the time | One |
| CFSRE toxicology detections at the time | None reported |
| Does this prove the pill is circulating in Tennessee? | No |
| Does it prove every B707 pill is counterfeit? | No |
Source: CFSRE NPS Discovery.
Why a Georgia Detection Matters to Tennessee
A state line does not isolate one community from another drug market. People travel between Tennessee and Georgia for work, school, family, nightlife, health care, and recovery services. Pills may also be sold through social media, encrypted messaging apps, acquaintances, and online markets rather than remaining in the state where a sample was first collected.
That does not mean we should describe the Georgia tablet as a confirmed Tennessee threat. Responsible drug-alert reporting requires a distinction between regional relevance and confirmed local circulation.
What the Georgia finding establishes is narrower but still important:
- A blue rectangular tablet marked B707 contained at least two novel benzodiazepines.
- The imprint created the appearance of a familiar 2 mg alprazolam product.
- The amount and combined strength of the two novel benzodiazepines were not reported.
- A person could not have identified the contents from the pill’s appearance.
- The effects of ethylflualprazolam have not been adequately characterized in humans.
The CDC has documented a broader national problem involving counterfeit pills made to resemble alprazolam and other prescription medications while containing illicit benzodiazepines, illegally manufactured fentanyl, or other unexpected substances.
What Is a B707 Pill Supposed to Contain?
Under the cited DailyMed product labeling, a legitimate B707 tablet contains 2 mg of alprazolam. It is described as light blue to blue, rectangular, and divided by three break lines, with two notches between the lines and “B707” on the opposite side.
Alprazolam is a prescription benzodiazepine used for anxiety and panic disorder. B707 is associated with a generic alprazolam product; it is not the imprint used on brand-name Xanax.
Pharmaceutical B707 vs. the Georgia Laboratory Sample
| Category | Legitimate B707 Product | Georgia B707-Style Sample |
|---|---|---|
| What the imprint represents | 2 mg alprazolam | A tablet visually resembling the labeled product |
| Confirmed substances | Alprazolam under the product label | Ethylflualprazolam and 4′-Cl deschloroalprazolam were confirmed |
| Dose information | Standardized 2 mg dose | Quantitative amounts were not provided |
| Manufacturing | Regulated pharmaceutical manufacturing | Unregulated drug-material sample |
| Human safety information | Established prescribing and safety information | Very limited compound-specific human data |
| Known onset and duration | Clinically characterized, although individual effects vary | Not adequately established |
| Reliable dose conversion | Measured in prescribed milligrams | No reliable alprazolam-equivalent conversion |
| Can appearance authenticate it? | No; the source must also be verified | No |
| Best evidence of authenticity | Dispensed by a licensed pharmacy in its original labeled container | Exact contents require laboratory analysis |
Sources: DailyMed and CFSRE.
Even a convincing color, shape, score pattern, or imprint cannot recreate the accountability of a licensed manufacturer, pharmacy record, and labeled prescription container. Brooks provides a broader guide to this issue in our article on counterfeit pills and fentanyl adulteration.
What Is Ethylflualprazolam?
Ethylflualprazolam is a newly identified triazolobenzodiazepine with structural similarities to alprazolam and flualprazolam. It belongs to a growing category of novel benzodiazepines that may be sold alone, added to other drugs, or pressed into tablets designed to resemble familiar prescription products.
CFSRE reported that very little published information was available about ethylflualprazolam’s pharmacology or potency. Its activity has been hypothesized to resemble flualprazolam, but that is not enough to establish a safe dose, predictable duration, or alprazolam conversion.
Ethylflualprazolam at a Glance
| Category | Current Information |
|---|---|
| Drug name | Ethylflualprazolam |
| Drug class | Novel or designer benzodiazepine |
| Chemical family | Triazolobenzodiazepine |
| Structurally related to | Alprazolam and flualprazolam |
| Established medical dose | None identified in the available alerts |
| Known human potency | Not established |
| Known onset | Not established |
| Known duration | Not established |
| Reliable alprazolam equivalent | None available |
| Reported Georgia finding | Blue rectangular tablet marked B707 |
| Other drug found in the tablet | 4′-Cl deschloroalprazolam |
| Expected class effects | Sedation, impaired coordination, slowed thinking, memory problems, confusion, and reduced consciousness |
| Major interaction concern | Alcohol, opioids, or other sedatives may substantially increase impairment and overdose risk |
| Can naloxone reverse it? | No; naloxone reverses opioids rather than benzodiazepines |
| Can a fentanyl test strip identify it? | No |
| Can a person identify it visually? | No |
The possible effects listed above are based largely on the benzodiazepine drug class. They should not be interpreted as a complete or precisely measured ethylflualprazolam profile.
What Is 4′-Cl Deschloroalprazolam?
The second substance identified in the tablet, 4′-Cl deschloroalprazolam, is also a novel benzodiazepine and central nervous system depressant.
It is structurally similar to alprazolam and is considered an alprazolam isomer. Isomers have the same molecular formula but a different arrangement of atoms. Their chemical similarity can complicate testing, although laboratories can distinguish the compounds through their unique mass-spectral fragments.
CFSRE previously identified 4′-Cl deschloroalprazolam in a toxicology sample in 2022 and noted that the substance had been found in pills collected in Australia in December 2021. CFSRE also reported that novel benzodiazepines have been associated with adverse events and fatalities, commonly when opioids, alcohol, or other depressants were involved.
4′-Cl Deschloroalprazolam at a Glance
| Category | Current Information |
|---|---|
| Drug name | 4′-Cl deschloroalprazolam |
| Other name | 4′-chloro deschloroalprazolam |
| Drug class | Novel or designer benzodiazepine |
| Relationship to alprazolam | Structurally similar and an isomer of alprazolam |
| Earlier reported appearance | Pills collected in Australia in December 2021 |
| Recent Georgia finding | Identified with ethylflualprazolam in the B707-style tablet |
| Known potency | Not reliably established |
| Known onset and duration | Not adequately established |
| Testing challenge | May require specialized confirmatory analysis to distinguish it from alprazolam |
| Potential class effects | Sedation, impaired balance, memory problems, slowed thinking, confusion, and reduced consciousness |
| Major interaction concern | Other benzodiazepines, opioids, alcohol, and additional central nervous system depressants |
| Dependence concern | Repeated benzodiazepine exposure may produce physical dependence |
| Key issue in this case | It was one of two novel benzodiazepines confirmed in a tablet carrying an alprazolam-associated imprint |
People researching this changing market can also read Brooks’ guides to bromazolam and etizolam.
What We Know (and What We Do Not Know)
Separating confirmed information from assumptions is essential when discussing a new drug alert.
| What the Report Establishes | What the Report Does Not Establish |
|---|---|
| The sample originated in Georgia | The city or county where it circulated |
| The tablet was blue, rectangular, and marked B707 | How many similar tablets existed |
| Ethylflualprazolam was confirmed | The amount of ethylflualprazolam in the tablet |
| 4′-Cl deschloroalprazolam was also identified | The ratio between the two benzodiazepines |
| Advanced laboratory methods were used | How a particular person would respond to the tablet |
| CFSRE had one drug-material detection at the time | That the substance was already widespread |
| No CFSRE toxicology detections had been reported at that time | That no one had ever taken or been harmed by the substance |
| The tablet carried an imprint associated with alprazolam | That every B707 tablet contains the same compounds |
| The public monograph did not provide a dose conversion | Whether the pill was weaker or stronger than 2 mg alprazolam |
| The pill was found in Georgia | That the same product had entered Tennessee |
Source: CFSRE NPS Discovery.
A new drug alert does not need to prove widespread distribution before it becomes useful. Its value is that it gives communities time to respond without exaggerating what is known.
Ethylflualprazolam Has Appeared in Different Drug Markets
The Georgia B707 tablet was not the first public signal involving ethylflualprazolam.
| Date and Location | What People Expected | What Testing Found |
|---|---|---|
| December 2025 — Toronto | Fentanyl samples | Ethylflualprazolam was found in three expected fentanyl samples during the reporting period |
| March 2026 — Australia | Alprazolam bars | Two bar-shaped pills contained ethylflualprazolam; neither contained alprazolam |
| April 2026 — Georgia | A tablet bearing an imprint associated with 2 mg alprazolam | Ethylflualprazolam and 4′-Cl deschloroalprazolam were confirmed |
Toronto’s Drug Checking Service first detected ethylflualprazolam on December 16, 2025. It described the substance’s strength and duration as unknown and found it in three samples that people expected to contain fentanyl.
In March 2026, Australia’s CanTEST program identified it in two bars expected to contain alprazolam. One was yellow and marked “R039,” while the other was white and marked “XANAX” and “02.” Neither sample contained alprazolam.
The Georgia finding adds another form to the timeline: a blue rectangular B707-style tablet. These reports do not reveal how common ethylflualprazolam has become, but they show that it has appeared in more than one country, more than one pill design, and more than one expected drug category.
Why Do Two Designer Benzodiazepines in One Pill Increase the Risk?
The Imprint Can Create a False Dose Expectation
Someone familiar with B707 may believe the tablet contains 2 mg of alprazolam. That assumption may influence how many pills they take, whether they combine the tablet with another substance, and how long they wait before taking more.
The Georgia report does not provide any scientific basis for treating the tablet as equivalent to 2 mg of alprazolam.
The Total Sedative Load Is Unknown
The laboratory confirmed two benzodiazepine-related substances, but the public report did not provide the amount of either one. There is no way to calculate the combined sedative effect from the imprint.
Even when two tablets look alike, unregulated manufacturing offers no assurance that their contents or strength will be identical.
Effects May Accumulate
Benzodiazepines slow activity in the central nervous system. Taking more than one benzodiazepine can increase drowsiness, memory impairment, poor coordination, confusion, blackouts, and the inability to remain conscious.
The interaction becomes more dangerous when opioids, alcohol, sleep medications, barbiturates, or other sedating substances are involved.
Unknown Duration Can Lead to Premature Redosing
A person may expect the pill to act like alprazolam. When the initial effect feels delayed, weak, or different, they may take another tablet.
Because ethylflualprazolam’s onset and duration are not established, repeat dosing can lead to unexpectedly deep or prolonged sedation.
Mixed Depressants Can Affect Breathing
Prescription alprazolam labeling warns that combining benzodiazepines with opioids can cause profound sedation, respiratory depression, coma, and death. Novel benzodiazepines introduce additional uncertainty because the dose and duration may not be known.
Possible Effects of an Unregulated B707 Pill
Direct human data on ethylflualprazolam remain limited. Based on the substances’ benzodiazepine classification, possible effects may include:
- Severe drowsiness or repeatedly falling asleep
- Slurred speech
- Dizziness or unsteady movement
- Poor coordination
- Slowed reactions
- Confusion or disorientation
- Memory gaps or blackouts
- Reduced judgment and disinhibition
- Difficulty standing or walking
- Loss of consciousness
- Slowed or impaired breathing, especially when opioids, alcohol, or other depressants are involved
Someone cannot determine whether these effects are being caused by alprazolam, ethylflualprazolam, 4′-Cl deschloroalprazolam, an opioid, or another substance simply by examining the tablet.
When Is It an Emergency?
Call 911 immediately when someone who took an unregulated or suspected counterfeit pill:
- Cannot be awakened
- Has collapsed or had a seizure
- Is breathing slowly, shallowly, irregularly, or not at all
- Makes choking, gurgling, or unusual snoring sounds while unresponsive
- Has blue, gray, pale, cold, or clammy skin
- Vomits while deeply sedated
- Cannot remain conscious or protect their airway
It can be difficult to distinguish heavy sedation from an overdose. The CDC recommends treating an uncertain situation as an overdose because acting quickly may save the person’s life.
What to Do During a Suspected Overdose
- Call 911 immediately. Tell the dispatcher that the person may have taken an unknown or counterfeit pill.
- Administer naloxone when it is available. Naloxone will not reverse ethylflualprazolam or another benzodiazepine, but it can reverse fentanyl or another opioid that may also be involved.
- Try to keep the person breathing. Follow the dispatcher’s instructions and provide rescue breathing or CPR when trained to do so.
- Place the person on their side. This can reduce the risk of choking if they vomit.
- Stay until emergency responders arrive. Do not leave an unresponsive person alone or allow them to “sleep it off.”
- Give responders as much information as possible. Mention the B707 imprint, the tablet’s color, when it was taken, how many pills may be involved, and whether alcohol, opioids, or other medications were also used.
CDC guidance recommends administering naloxone when available, calling 911, keeping the person awake and breathing when possible, placing them on their side, and remaining with them until help arrives.
Harm Reduction for B707 and Other Xanax-Style Pills
The only reliable way to know that a medication contains the labeled pharmaceutical ingredient is to obtain it through a licensed pharmacy with a valid prescription.
When a person is at risk of taking unregulated pills, practical harm-reduction steps include:
- Do not rely on the imprint, color, shape, score lines, or packaging.
- Do not combine an unknown pill with alcohol, opioids, or other sedatives.
- Do not use alone. Someone should be present who can recognize an emergency and call 911.
- Do not take additional tablets because the first one feels different or appears slow to take effect.
- Keep naloxone nearby. It cannot reverse benzodiazepines, but it may reverse an undisclosed opioid component.
- Understand the limits of fentanyl test strips. They do not detect ethylflualprazolam or 4′-Cl deschloroalprazolam.
- Seek a medical evaluation when use has become frequent or daily. Abruptly stopping regular benzodiazepine exposure can be dangerous.
No amount of an unregulated B707-style tablet can be assumed safe based on its appearance.
Why a Negative Fentanyl Test Does Not Authenticate a B707 Pill
Fentanyl test strips are designed to indicate whether fentanyl may be present in a sample. They cannot tell someone that a tablet contains pharmaceutical alprazolam, measure the dose, or identify designer benzodiazepines.
A negative fentanyl result therefore does not mean:
- The pill is a legitimate B707 tablet
- The pill contains 2 mg of alprazolam
- Ethylflualprazolam is absent
- 4′-Cl deschloroalprazolam is absent
- The tablet contains no other dangerous substance
- The pill has a predictable strength or duration
The Georgia identification required GC-MS and LC-QTOF-MS analysis compared with authenticated reference material. A visual inspection or fentanyl strip cannot provide the same information.
Do Not Stop Daily Benzodiazepine Use Suddenly
Someone taking street B707 pills or other Xanax-style tablets regularly may become physically dependent without knowing which benzodiazepine, or combination of benzodiazepines, they have been using.
The FDA warns that physical dependence can develop even when benzodiazepines are taken as prescribed. Abrupt discontinuation or rapid dose reduction can cause serious and potentially life-threatening withdrawal reactions, including seizures.
Possible withdrawal symptoms include:
- Severe anxiety or panic
- Tremors
- Sweating
- Insomnia
- Agitation
- Increased heart rate
- Sensitivity to light or sound
- Confusion
- Hallucinations
- Muscle twitching
- Seizures
An online conversion chart cannot safely translate an unknown amount of ethylflualprazolam and 4′-Cl deschloroalprazolam into an alprazolam taper. Medical providers need to consider the person’s frequency of use, last dose, withdrawal history, prior seizures, other substances, and current symptoms.
Brooks provides benzodiazepine addiction treatment with medical oversight and individualized planning. Someone taking these pills daily should seek guidance rather than attempting to stop cold turkey.
Brooks’ Work With Local Harm-Reduction Coalitions
Treatment and harm reduction are not opposing strategies. Both begin with the same requirement: the person must remain alive long enough to recover.
Brooks Healing Center supports the work of the Warren County Prevention and Intervention Coalition, which provides prevention education, naloxone distribution, overdose-prevention workshops, community outreach, and connections to local support.
Brooks was listed as a sponsor of the coalition’s first Recovery Fest in 2025. We also supported the unveiling of The Caring Library, a permanent, judgment-free Narcan distribution resource, by providing lunch for the community event.
The coalition’s current free Narcan map lists Caring Library locations in McMinnville, including:
- Steered Straight: 1714 Smithville Highway, McMinnville, TN 37110
- Arbor Church of the Nazarene: 918 Sparta Street, McMinnville, TN 37110
Narcan is available at these locations at no cost and without questions while supplies last. The coalition also offers overdose-response education and free Narcan training.
We support this work because naloxone access, accurate drug alerts, stigma reduction, and connection to treatment form a continuum. Naloxone may save someone during one emergency. Detox and ongoing treatment can help prevent the next one.
Tennessee and Georgia Overdose Resources
| Resource | How It Helps |
|---|---|
| Emergency response | Call 911 when someone cannot be awakened, is having a seizure, or is breathing abnormally |
| Brooks Healing Center | Call 931-486-8824 or visit our contact page |
| Free Narcan in Warren County | Use the Caring Library location map |
| Warren County coalition | Find education, Narcan training, events, and community resources at WarrenPrevention.org |
| Tennessee Regional Overdose Prevention Specialists | Find free naloxone education, training, and regional contacts through the Tennessee ROPS program |
| Tennessee REDLINE | Call or text 800-889-9789 for free, confidential treatment referrals |
| Georgia Crisis and Access Line | Call 1-800-715-4225 for crisis support, detox-bed assistance, and connections to Georgia services |
| 988 Suicide & Crisis Lifeline | Call or text 988 during a mental health or behavioral health crisis |
Tennessee’s ROPS program provides overdose-prevention training and naloxone distribution across the state. The Tennessee REDLINE provides free and confidential referrals to addiction treatment.
Georgia’s Crisis and Access Line operates 24 hours a day and can help locate crisis or detox services throughout the state.
When Has Benzodiazepine Use Moved Beyond Harm Reduction?
Harm-reduction resources are important at every stage, but certain signs indicate that immediate clinical help may be needed:
- Taking B707 tablets or other benzodiazepines every day
- Experiencing shaking, sweating, anxiety, or insomnia between doses
- Taking pills to feel normal or avoid withdrawal
- Needing increasingly larger amounts
- Having frequent blackouts or unexplained memory gaps
- Mixing benzodiazepines with alcohol or opioids
- Continuing after an overdose or emergency-room visit
- Purchasing pills from social media, friends, or unregulated online sellers
- Being unable to confirm what is in the pills
- Trying unsuccessfully to reduce or stop
- Hiding purchases or use from family members
- Feeling unable to work, sleep, socialize, or function without the pills
- Having a history of withdrawal seizures or hallucinations
Dependence can happen to someone who began with a legitimate prescription, someone taking pills recreationally, or someone unknowingly using designer benzodiazepines. None of these situations makes a person unworthy of compassionate care.
Benzodiazepine Detox and Treatment at Brooks Healing Center
Brooks Healing Center provides a continuum of addiction treatment in Normandy, Tennessee, including services for people traveling from North Georgia, Marietta, Chattanooga, Nashville, and surrounding communities.
Medical Assessment and Detoxification
Benzodiazepine withdrawal can involve seizures and other serious complications. Our medical detox program provides 24-hour support and monitoring in a structured environment.
When the pills came from an unregulated source, the assessment may need to account for:
- An uncertain active ingredient
- Unknown pill strength
- More than one benzodiazepine
- Possible opioid or alcohol use
- Prior withdrawal attempts
- A history of seizures
- Anxiety, trauma, insomnia, or other co-occurring concerns
Brooks’ benzodiazepine treatment program is built around safety, medical oversight, and an individualized approach rather than a one-size-fits-all withdrawal timeline.
Residential Treatment
Detox addresses immediate physical stabilization, but it does not resolve the circumstances that led to repeated use.
Our residential treatment program gives clients time away from unregulated drug access, environmental triggers, and daily pressures while they participate in structured clinical care.
Treatment can address:
- Anxiety or panic symptoms
- Trauma
- Sleep problems
- Polysubstance use
- Relapse patterns
- Emotional regulation
- Family relationships
- Recovery planning
Dual-Diagnosis Care
Many people begin taking benzodiazepines because they are trying to manage anxiety, panic attacks, trauma symptoms, or insomnia. Removing the pills without addressing those concerns can leave the person vulnerable to relapse.
Dual-diagnosis treatment at Brooks addresses substance use and co-occurring mental health needs together.
Continuing Care Through PHP and IOP
Following detoxification or residential treatment, some clients continue through a partial hospitalization program or intensive outpatient program. Step-down care helps people practice recovery skills while maintaining meaningful clinical and peer support.
When opioid or alcohol use disorder is also present, medication-assisted treatment may be considered for that part of the treatment plan. MAT is used for opioid and alcohol use disorders; it is not a direct antidote or replacement treatment for designer-benzodiazepine withdrawal.
Treatment for Georgia Residents
Brooks serves people from Georgia, including Marietta and Cobb County who need to step away from their immediate environment for detoxification or residential treatment. Our Normandy location offers a structured setting a few hours from the greater Atlanta area.
Call 931-486-8824 to discuss benzodiazepine use, withdrawal concerns, treatment options, or travel arrangements. You can also verify your insurance benefits confidentially. In an overdose or active medical emergency, call 911 before contacting an admissions program.
Frequently Asked Questions
Does every blue B707 pill contain ethylflualprazolam?
No. The CFSRE report involved one drug-material sample originating in Georgia. Legitimate B707 alprazolam products also exist. The concern is that an unregulated tablet cannot be authenticated by its appearance or imprint.
Is B707 the same as Xanax?
A legitimate B707 tablet contains 2 mg of generic alprazolam. Alprazolam is commonly associated with the brand name Xanax, but B707 is a generic-product imprint rather than the imprint for brand-name Xanax.
Was fentanyl found in the Georgia B707 tablet?
CFSRE’s public monograph identifies ethylflualprazolam and 4′-Cl deschloroalprazolam as the reported findings. It does not report fentanyl as the central finding in this sample. That should not be interpreted to mean that other unregulated B707 tablets are fentanyl-free. Counterfeit pills can have entirely different ingredients from one product or source to another.
Is ethylflualprazolam stronger than alprazolam?
That has not been established. Available research is too limited to provide a dependable potency comparison or an alprazolam-equivalent dose.
Can naloxone reverse ethylflualprazolam?
No. Naloxone reverses opioid effects, not benzodiazepine effects. It should still be administered during a suspected overdose when an opioid may also be present. Naloxone is considered safe to give when a person is not actually experiencing an opioid overdose. Call 911 regardless of the initial response.
Will a fentanyl test strip detect ethylflualprazolam?
No. Fentanyl test strips do not identify ethylflualprazolam, 4′-Cl deschloroalprazolam, or pharmaceutical alprazolam. A negative strip does not authenticate a pill.
Can someone identify a real B707 by looking at the score lines?
No. Unregulated manufacturers can imitate colors, imprints, shapes, and score patterns. A loose tablet’s appearance cannot confirm its active ingredient or dose.
Is it safe to stop taking street B707 pills cold turkey?
No abrupt stop can be assumed safe after regular benzodiazepine use. Sudden discontinuation may cause severe withdrawal, including seizures. A medical assessment is particularly important when the exact substance and dose are unknown.
Sources
Center for Forensic Science Research and Education. (2026, April 28). Ethylflualprazolam: NPS Discovery new drug monograph.
https://www.cfsre.org/images/monographs/Ethylflualprazolam-New-Drug-Monograph-NPS-Discovery.pdf
Center for Forensic Science Research and Education. (2022, December 7). 4′-Cl deschloroalprazolam.
https://www.cfsre.org/images/monographs/4-Cl-Deschloroalprazolam-120722-CFSRE-Toxicology-Report.pdf
National Library of Medicine. (n.d.). Alprazolam tablets, USP. DailyMed.
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=9af0b80f-b708-9709-e053-2995a90a9251&type=display
Toronto’s Drug Checking Service. (2025, December 26). 126 samples checked: December 13–26, 2025.
https://drugchecking.community/report/december-13-26-2025/
The Know. (2026, March 27). Ethylflualprazolam found in expected “alprazolam” pills.
https://theknow.org.au/alerts_warnings/ethylflualprazolam-found-in-expected-alprazolam-pills/
Centers for Disease Control and Prevention. (2023). Drug overdose deaths with evidence of counterfeit pill use—United States, July 2019–December 2021.
https://www.cdc.gov/mmwr/volumes/72/wr/mm7235a3.htm
Centers for Disease Control and Prevention. (2024). What to do if you think someone is overdosing.
https://www.cdc.gov/stop-overdose/response/index.html
Centers for Disease Control and Prevention. (2024). 5 things to know about naloxone.
https://www.cdc.gov/overdose-prevention/reversing-overdose/about-naloxone.html
U.S. Food and Drug Administration. (2020). FDA requiring boxed warning updated to improve safe use of benzodiazepine drug class.
https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class
Tennessee Department of Mental Health and Substance Abuse Services. (n.d.). Regional Overdose Prevention Specialists.
https://www.tn.gov/behavioral-health/substance-abuse-services/prevention/rops.html
Warren County Prevention and Intervention Coalition. (n.d.). Warren County Prevention and Intervention Coalition.
https://warrenprevention.org/
Warren County Prevention and Intervention Coalition. (2025, September 5). The Caring Library: A safe space for Narcan access.
https://warrenprevention.org/2025/09/05/the-caring-library-free-narcan/
Warren County Prevention and Intervention Coalition. (n.d.). Free Narcan Warren County—Find a Caring Library near you.
https://warrenprevention.org/free-narcan-warren-county/
Georgia Department of Behavioral Health and Developmental Disabilities. (n.d.). The crisis system of Georgia.
https://dbhdd.georgia.gov/be-dbhdd/crisis-system-georgia
